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Unresolved problems with thrombolytic therapy. During 
the last 6 years, coronary thrombolysis has rapidly become 
established as a major advance in the treatment of selected 
patients with acute myocardial infarction. When successful, 
thrombolysis causes reperfusion of occluded coronary arter- 
ies, salvages ischemic myocardium, prevents left ventricular 
dysfunction and enhances both early and late survival. 
However, unresolved problems with this therapy persist (1). 
First, coronary arteriography carried out immediately after 
intravenous infusion of the thrombolytic agent demonstrates 
that reperfusion of the infarct-related artery does not occur 
uniformly. After the intravenous administration of recombi- 
nant tissue-type plasminogen activator @t-PA), perhaps the 
most effective thrombolytic agent now available, approxi- 
mately 25% of patients exhibit persistent coronary occlusion 
(2). Other limitations of thrombolytic therapy include a 
modest incidence of reocclusion and bleeding complications. 
Furthermore, there is debate concerning the identification of 
appropriate patients for treatment, especially patients with 
ST segment depression, as well as patients presenting >6 h 
after the onset of symptoms (1). Other unresolved problems 
include selection of the appropriate adjuvant therapy to 
prevent reocclusion and to minimize reperfusion injury. 
The present study. The lack of therapeutic efficacy is an 
especially vexing problem. Not unexpectedly, mortality is 
particularly high in patients whose occluded coronary artery 
fails to open (3). This potentially serious limitation of effi- 
cacy appears to have been addressed successfully by Neu- 
haus et al. (4) in a simple and straightforward manner. These 
investigators “front loaded” the dose, commencing with a 
bolus of 15 mg, followed by 50 mg in the next 30 min and the 
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remaining 35 mg in the following 60 min. Coronary patency, 
defined as Thrombolysis in Myocardial Infarction (TIMI) 
class 2 or 3 (5), was observed in 90.5% of 74 patients studied 
arteriographically at 90 min. To my knowledge, this is the 
highest patency rate following the intravenous administra- 
tion of any thrombolytic agent thus far reported, and it is 
apparently superior to the approximately 75% patency rate 
previously reported with the standard rt-PA regimen (60 mg 
for 1 h with a 6 to 10 mg bolus dose and 20 mg during each 
of the subsequent 2 h). This salutary result was not associ- 
ated with an excessive rate of reocclusion (10.5%) or bleed- 
ing. 
Although these observations are impressive and encour- 
aging, before recommending the widespread adoption of the 
“Neuhaus regimen,” it is desirable to carry out a controlled 
randomized trial comparing it with the standard regimen. It 
might be even more appropriate to compare the “front- 
loaded” Neuhaus regimen with the standard regimen using 
weight-adjusted doses because the latter not only is more 
logical, but also may have some advantages over the fixed 
100 mg dose (6). Such a comparison is essential to evaluate 
this new regimen because of the well known problems 
associated with the use of historical controls and because, in 
most of the earlier studies with rt-PA, angiographic patency 
was assessed at approximately 90 min after the onset of 
therapy, before the infusion of the full dose, thereby proba- 
bly underestimating thrombolytic efficacy. However, if the 
results of an appropriately controlled comparison confirm 
the superiority of the “Neuhaus regimen,” then it (or a 
weight-adjusted modification) should be substituted for the 
standard approach. 
Implications. Currently there is considerable interest in 
the use of genetically engineered mutants of t-PA (7) whose 
principal advantage over native t-PA appears to be a longer 
half-life measured in hours instead of minutes. These mu- 
tants can be administered as a bolus rather than an infusion, 
and such a bolus can rapidly achieve a high concentration of 
circulating drug. If, as is strongly suggested by the data of 
Neuhaus et al. (4), rapidly achieving a high concentration of 
IX-PA enhances thrombolysis, then it is possible that this 
advantage will also be attained with the bolus injection of 
appropriate mutants that may possess the additional desir- 
able feature of providing a sustained high plasma concentra- 
tion, thus avoiding the need for more than one injection. 
Although thrombolytic therapy is now well established 
treatment for many patients with acute myocardial infarc- 
tion, considerable “fine tuning” is necessary to enhance its 
efficacy and broaden its applicability. The study by Neuhaus 
et al. (4) may well prove to be a useful contribution of this 
nature. 
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